5 Easy Facts About Ponsegromab Described
All enrolled individuals who been given at least one particular dose of zosuquidar or placebo in the course of induction have been monitored for that prevalence of adverse occasions (439 sufferers, 219 on zosuquidar and 210 on placebo). The most typical adverse situations were being relevant to the duration of extended and sizeable myelosuppression